Clinical Trials Directory

Trials / Completed

CompletedNCT00354029

Effect of Perioperative i.v. Low-dose S(+) Ketamine

Effect of Perioperative i.v. Low-dose S(+) Ketamine in Patients Undergoing Hemorrhoidectomy

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
83 (actual)
Sponsor
Asker & Baerum Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether the use of perioperative intravenous S (+) ketamine reduces the amount and degree of postoperative pain. Furthermore the purpose of this study is to determine whether the use of perioperative intravenous S (+) ketamine effects cognitive function in the early postoperative period.

Detailed description

The mechanism of development of postoperative pain is complex. Central and peripheral sensitization are playing an important role and this can lead to postoperative hypersensitization. Several studies have shown, that S (+) ketamine can be effective to reduce sensitization and postoperative pain. Ketamine (2-O-chlorophenyl-2-methylamino cyclohexanone) is a N-Methyl-D-Aspartat (NMDA) receptor antagonist. S (+) ketamine has a four times stronger affinity to the NMDA receptor compared to R (-) ketamine. The duration of action for S (+) ketamine is shorter than R (-) ketamine and it has fewer side-effects. The purpose of this study is to compare the analgetic effect of pregabalin and placebo used in the perioperative period. The hypothesis is that perioperative intravenous S (+) ketamine gives significant better analgesia than placebo without effecting cognitive function. The study is including patients undergoing hemorrhoidectomy.

Conditions

Interventions

TypeNameDescription
DRUGS (+) Ketamine0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
DRUGPlaceboisotonic saline

Timeline

Start date
2006-08-01
Primary completion
2008-06-01
Completion
2009-05-01
First posted
2006-07-19
Last updated
2011-07-20
Results posted
2011-07-20

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT00354029. Inclusion in this directory is not an endorsement.